Shifting Medicare Part B drug coverage into Medicare Part D.

Reducing Medicare Part D co-pays for generic drugs.

Increasing the number of pharmacy benefit managers.

Establishing expedited review for new versions of brand-name drugs.

Tying U.S. drug prices to prices paid for the same drugs in other countries.

Using U.S. trade policies to compel other countries to pay more for American pharmaceutical products.

These are among the ideas presented in a new report by the White House Council of Economic Advisers detailing steps that might be taken to reduce prescription drug prices in the U.S.

To learn more about these and other ideas, go here to see the White House Council of Economic Advisers report Reforming Biopharmaceutical Pricing at Home and Abroad.